Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.
Sophie MarbaixWilly E PeetermansJan VerhaegenLieven AnnemansReiko SatoAnnick MignonMark AtwoodDerek WeyckerPublished in: PloS one (2018)
Reimbursement of PCV13 in moderate/high-risk Belgian adults aged 65-84 years would be cost-effective from the Belgian healthcare perspective.
Keyphrases